Five-Year Plan Is A Titration Curve

Candidate brought a hand-drawn dose-escalation chart to the interview. HR brought a chokehold.

Filed under Retatrutide ·Cagrilintide ·Survodutide · #stack-life ·#glp-1 ·#cope

Active Compounds

Retatrutide · Triple GIP/GLP-1/Glucagon Receptor Agonist

An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.

Cagrilintide · Amylin Analogue

A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

RX: Retatrutide · Cagrilintide · Survodutide
Dosage: 2mg → 12mg over 20 weeks
Half-life: until vesting cliff
Source: manual
Tags: stack-life , glp-1 , cope
Stamped: 2026-05-21 · Cycle 021
Lot #: LOT-20260521T16:09:43.855Z